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Abstract
Background: Bloodstream infection is common in the UK and has significant mortality depending on the
pathogen involved, site of infection and other patient factors. Healthcare staffing and ward activity may also impact
on outcomes in a range of conditions, however there is little specific National Health Service (NHS) data on the
impact for patients with bloodstream infection. Bloodstream Infections – Focus on Outcomes is a multicentre cohort
study with the primary aim of identifying modifiable risk factors for 28-day mortality in patients with bloodstream
infection due to one of six key pathogens.
Methods: Adults under the care of five NHS Trusts in England and Wales between November 2010 and May 2012
were included. Multivariable Cox regression was used to quantify the association between modifiable risk factors,
including staffing levels and timing of appropriate therapy, and 28-day mortality, after adjusting for non-modifiable
risk factors such as patient demographics and long-term comorbidities.
Results: A total of 1676 patients were included in the analysis population. Overall, 348/1676 (20.8%) died within 28
days. Modifiable factors associated with 28-day mortality were ward speciality, ward activity (admissions and
discharges), movement within ward speciality, movement from critical care, and time to receipt of appropriate
antimicrobial therapy in the first 7 days. For each additional admission or discharge per 10 beds, the hazard
increased by 4% (95% CI 1 to 6%) in medical wards and 11% (95% CI 4 to 19%) in critical care. Patients who had
moved wards within speciality or who had moved out of a critical care ward had a reduction in hazard of mortality.
In the first 7 days, hazard of death increased with increasing time to receipt of appropriate antimicrobial therapy.
Conclusion: This study underlines the importance of appropriate antimicrobials within the first 7 days, and the
potential for ward activity and ward movements to impact on survival in bloodstream infection.
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Key points
Modifiable risk factors associated with 28-day mortality
after BSI are ward speciality, ward activity, ward move-
ment within speciality, movement from critical care and
time to receipt of appropriate antibiotics in the first 7
days.
Background
At least 100,000 patients have an episode of bloodstream
infection (BSI) each year in England, Wales and North-
ern Ireland [1]. Depending on the pathogen involved,
underlying patient characteristics, the severity of infec-
tion and treatment provided the death rate from these
infections can reach 15–25% at 30 days and 50% at 3
years [2–4]. Poor outcomes are known to be related to
several non-modifiable patient factors including age,
comorbidities, severe sepsis, source of infection,
neutropenia, type of infection, and intensive care (ICU)
admission [2, 5–10]. In contrast, timely appropriate
antimicrobial chemotherapy and removal of infected
prosthetic materials have been found to be beneficial –
but data are typically from single-centre studies, and
information on the estimated size of these effects is
limited. Staffing levels are known to impact a range of
care quality measures, including patient mortality [11–
13]. In addition, nursing skill mix and the use of non-
permanent staff may increase the rates of hospital-
acquired infection [14]. However there is less informa-
tion on the impact of staffing on infection outcomes in
general, and none on its impact on BSI outcomes in
particular [14, 15].
The Bloodstream Infections – Focus on Outcomes
(BSI-FOO) study is a prospective cohort study designed
to quantify modifiable risk factors for death (from all
causes) within 28 days of onset of BSI caused by six key
pathogens: 1) methicillin-resistant Staphyloccos aureus
(MRSA); 2) methicillin-susceptible S. aureus (MSSA); 3)
non-Extended-spectrum beta-lactamase (ESBL)-produ-
cing Escherichi coli; 4) any ESBL-producing member of
the family Enterobacteriales; 5) Pseudomonas aeruginosa;
6) any species of Candida.
Methods
Study design
BSI-FOO is a prospective multicentre cohort study con-
ducted across five NHS acute hospital trusts in England
and Wales. The study period was from November 2010
to May 2012, but for administrative reasons the study
opened and closed on different dates in the five centres.
Data were collected from routine care, investigations or
tests and recorded according to usual clinical practice.
The National Information Governance Board approved
the use of such routinely collected data without individ-
ual patient consent under section 251 of the NHS Act
2006. Patients were followed up for 28 days from the
date the diagnostic blood sample was taken.
Study population
Adults (≥18 years old) receiving in-patient NHS hospital
care and having a clinically significant BSI with an or-
ganism in one or more of the six key pathogen groups
were included. Non-ESBL-producing E. coli is one of the
most prevalent pathogen of BSI in the UK, so to ensure
all pathogen groups were adequately represented, a
random sample of one-third of episodes caused by non-
ESBL-producing E. coli and all episodes caused by the
other six key pathogens were included. The number of
cases at each of the hospitals during the study period
determined the sample size.
Patients with HIV-positive serology, cystic fibrosis, on
an end-of-life care pathway when the blood sample was
taken, in the custody of HM Prison Service of England
or Wales, not receiving NHS care, not an in-patient
when the blood sample was taken and not admitted
shortly afterwards, or discharged on the day the sample
was taken, with notes irretrievably missing or a general-
ised refusal to take part in research noted in medical
records were excluded. Duplicate blood cultures i.e.
samples from the same infection episode, were also
excluded.
Outcome measures
The primary outcome was time to death up to 28 days
of taking the diagnostic positive blood sample. Death
within seven days was a secondary outcome. Other out-
comes, to be reported elsewhere, were time to resolution
of fever, and length of hospital stay.
Risk factors
An episode of infection began when the first positive
blood sample confirming BSI was taken (defined as day/
time 0). Any factors present before time 0 were
considered non-modifiable (see Supplemental Table 1,
Additional file 1). Modifiable risk factors considered
were aspects of hospital care received from time 0 on-
wards, which included staffing levels, ward activity
(number of admissions/discharges), movements between
wards, timing of appropriate therapy and continuing
presence of intravenous lines and catheters (see Supple-
mental Table 2, Additional file 1). Within each centre,
ward level information including ward speciality, staffing
and activity was collected from day 0 to 7, for the ward
where the patient spent most of their day. Overall
staffing levels, including healthcare assistants, trust-
employed nurses and agency nurses, was averaged across
three shifts (early, late and night) and defined as staff:
bed ratio (number of staff per bed). Ward activity per
ped was defined similarly. The presence or absence of
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central lines, peripheral lines and urinary catheters was
observed on day 0, and their presence on days 1 to 28
determined using the date of removal.
Antimicrobial therapy was defined as ‘appropriate’ if
the organism was susceptible to the antimicrobial
prescribed, and therapy continued for at least 36 h to
allow therapeutic effect. Susceptibility was judged first
by test results for the antimicrobial prescribed (if
available), then by inference from test results for
related antimicrobials. In the absence of any relevant
test results, susceptibility was deduced from the
inherent susceptibility/resistance profile for the spe-
cies concerned [16]. If treatment was changed from
one appropriate antimicrobial to another, this was
treated as a single period of appropriate therapy pro-
viding that the next therapy began within 24 h of the
last dose of the previous therapy.
Statistical analyses
The analysis population consisted of all eligible partici-
pants entered into the study. Repeat episodes (distinct
infection episodes within the same patient) and patients
with polymicrobial episodes (infections involving more
than one microbial species) were excluded. The statis-
tical model was built in two stages:
Stage one model
The non-modifiable risk factors were assessed univari-
ately and factors associated with mortality were
identified using Cox regression analysis with a 20%
significance level. These identified factors were then
considered for inclusion in a multivariable model with
factors identified using backwards selection. The
estimated ln(hazard ratio) for each factor included in
the model were then used to derive a “risk score” for
each patient. The proportional hazards assumption
was assessed and if the assumption was not met then
the model was stratified by the variable(s) causing
non-proportional hazards. Multivariable fractional
polynomial models were used to select the best-fitting
functional form for continuous variables.
Stage two model
All modifiable risk factors were included in the model
regardless of statistical significance, with organism and
the risk score derived in stage one included as covari-
ates. Episodes were split at daily intervals from day 0 to
28 with ward speciality, central line, peripheral line,
urinary catheter, ward movements, staffing levels, ward
activity, and antimicrobial therapy variable values
updated at each interval (see Supplemental Table 2,
Additional file 1). Ward data was only collected up to
day 7 and so for patients who survived and were dis-
charged after day seven, ward speciality, staffing, ward
activity and ward movements were assumed be constant
for the remaining days (up to death/discharge or day
28). For risk factors which were bounded by survival
time e.g. time to receipt of appropriate therapy and
number of ward movements, time-dependent variables
were used within the data framework. The value of the
time-dependent exposure was calculated as a cumulative
count of ward movements up until that day. So, for each
day at risk, the ward movement count was increased by
one if the patient moved wards or remained the same if
the patient did not. Similarly, a cumulative count of days
before first receipt of appropriate antimicrobial therapy
was used. That is, on day 0 time to receipt of appropri-
ate therapy was 0 for all patients, remaining at 0 each
day for patients who received appropriate therapy on
day 0 otherwise increasing by one for each additional
day until receipt of first appropriate therapy. This
ensured that on day 3, for example, the maximum time
to appropriate therapy was 3 days, for both survivors and
deceased.
Interactions between ward speciality and ward activity
and between ward speciality and staffing levels were in-
cluded in the model regardless of statistical significance.
The following interaction terms were then considered
for potential inclusion: organism with each of risk score,
central line, peripheral line, urinary catheter and time to
appropriate antimicrobial therapy, and ward speciality
with within-ward speciality movements. A forward step-
wise approach was taken to select interactions to be in-
cluded in the final model, using likelihood ratio tests to
compare nested models with a 10% significance level.
This level was chosen to increase statistical power whilst
ensuring that not the number of events per variable did
not exceed 10 [17].
Model fit was assessed using standard methods and
calibration was assessed by comparing observed event
rate for patients in each decile of predicted event
rates. Collinearity was examined using the variance
inflation factor with values < 5 considered acceptable.
The proportional hazards assumption was assessed as
for the stage one model. If non-proportional hazards
were indicated, then time was categorised into periods
where proportional hazards appeared valid and an
interaction between this categorised time and the
variable with non-proportional hazards was added to
the model.
The risk score derived from the stage one model was
also used for the analysis for the secondary outcome, so
only stage two was repeated for 7-day mortality.
Missing data was assumed to be missing at random
and missing values were imputed using multiple imput-
ation (45 imputations) and the results were combined
using Rubin’s rules. Non-normally distributed variables
were transformed prior to imputation. If a suitable
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transformation could not be found or the imputation
procedure imputed values outside valid ranges then pre-
dictive mean matching was used for the imputation of
that variable. All variables that were in the primary ana-
lysis model, potential auxiliary variables (Supplemental
Table 1, Additional file 1), indicator for death and the
log of survival time were included in the imputation pro-
cedure. We intended to allow for any interaction terms
in the main analysis model in the imputation procedure
by imputing separately for each category of one of the
variables involved in any interactions. However, unfortu-
nately, the imputation procedure would not converge,
and it was not possible to include the interactions in the
imputation. The model selection process was performed
on a single imputed dataset so that log-likelihood statis-
tics could be calculated and compared. All analyses were
performed in Stata version 14.0 (StataCorp LP, College
Station, Texas, USA).
Sensitivity analysis
In the main analysis, an antimicrobial treatment was
considered ‘appropriate’ if the organism was susceptible
to the antimicrobial prescribed and the therapy contin-
ued for at least 36 h; and was not considered appropriate
if the patient died within 36 h of starting treatment.
However, this may lead to inflated effect estimates as the
death could be viewed as a consequence of not receiving
the therapy. A sensitivity analysis with the “36-h rule”
removed was performed to assess this possibility and we
also investigated a 12-h and 24-h rule. A complete case
analysis was also performed to assess the impact of the
multiple imputation.
Results
In total, 1828 patients (1903 eligible blood samples) were
recruited; 227 repeat and/or polymicrobial episodes were
excluded leaving an analysis population of 1676 patients:
116 with Candida, 168 ESBL-producing Enterobacter-
iales, 542 E. coli, 237 P. aeruginosa, 513 MSSA and 100
MRSA (Supplemental Figure 1, Additional file 1).
Patients with P. aeruginosa had the highest death rate
within 28 days (30.4%; 95% confidence interval (CI) 24.6
to 36.7%) and non-ESBL-producing E. coli the lowest
(13.3%; 95% CI 10.5 to 16.4%). Patients with MSSA and
ESBL producers experienced similar death rates (20.9%;
95% CI 17.4 to 24.6% and 20.2%; 95% CI 14.4 to 27.1%
respectively), as did patients with MRSA and Candida
(29.0%; 95% CI 20.4 to 38.9% and 29.3%; 95% CI 21.2 to
38.5%). A Kaplan-Meier curve for the unadjusted sur-
vival rates is given in Fig. 1.
Non-modifiable factors including demography and pa-
tient comorbidities are summarised by 28-day survival
status in Table 1 and Supplemental Table 3, Additional
file 1. Approximately 55% of the patients were male,
with a median age of 68.5 years (interquartile range
(IQR) 53.0 to 80.0).
Modifiable risk factors and the presence of lines are
summarised by 28-day survival status in Table 2 and
Supplemental Table 4, Additional file 1. Approximately
two-thirds of patients had a line present at time 0 and
both central and peripheral lines at time 0 were more
common in patients who died (30.5% vs 22.6, and 62.5%
vs 46.8%, respectively). The average number of nurses
per 10 beds on day 0 was slightly higher for patients
who died compared to those who survived (median 1.7
nurses [IQR 1.2 to 7.0] vs 1.4 [IQR 1.1 to 2.1]). Ward ac-
tivity on day 0 was similar with a median of 3.7 admis-
sions/discharges per 10 beds (IQR 1.9 to 7.3) for patients
who survived and 3.5 admissions/discharges per 10 beds
(IQR 1.8 to 5.5) for patients who died. Overall, 84.5% of
patients (1416/1676) received appropriate antimicrobial
therapy with a median time to receipt of 7 h (IQR 1–40)
(Supplemental Table 5, Additional file 1).
There was some suggestion of slightly reduced num-
bers of nurses at weekends compared to weekdays, but
the average number of health care assistants (HCA) and
agency staff did not appear to change throughout the
course of a week (Supplemental Figure 2, Additional file
1). Ward activity followed a similar trend to that of nurs-
ing levels, the quietest days being Saturday and Sunday
with a median of 1.8 (IQR 1.5 to 4.5) and 1.5 (IQR 0.7 to
2.9) admissions/discharges per 10 beds, respectively,
compared to a median above 3 on all other days
(Supplemental Figure 3, Additional file 1).
All patients were followed up for the full 28-day
follow-up period and were therefore not censored at
hospital discharge. The model used to derive the risk
score from non-modifiable risk factors for mortality is
shown in Supplemental Table 6, Additional file 1. The
model for modifiable risk factors, after adjusting for risk
score and organism is detailed in Fig. 2 and Supplemen-
tal Table 7, Additional file 1. Interaction terms that were
included in the model (p < 0.1) were i) risk score by ward
speciality, ii) time to receipt of appropriate antimicrobial
therapy by organism. Model checks suggested that the
hazards for time to receipt of appropriate antimicrobial
therapy were not proportional. Therefore, follow-up
time was categorised into three intervals: days 0–6, days
7–13, and day 14 onwards, and the effect of time to ap-
propriate antimicrobial therapy was estimated separately
for each interval.
The final model indicated that ward speciality (ICU),
increased ward activity, and time to receipt of appropri-
ate antimicrobial therapy in the first 7 days were associ-
ated with increased hazard of death and ward speciality
(surgical), movement within ward speciality and move-
ment from a critical care ward were associated with de-
creased hazard of death within 28 days, after adjustment
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for risk score and all other factors included in the model
(Fig. 2).
The effect of risk score on mortality was greatest for
patients in surgical (Hazard ratio (HR) 2.89; 95% CI 2.13
to 3.90) and medical wards (HR 2.77; 95% CI 2.35 to
3.27). For patients in critical care, the effect was still
highly statistically significant, but with a smaller effect
size (HR 1.84; 95% CI 1.54 to 2.19). The presence of cen-
tral lines, peripheral lines and urinary catheters were not
significantly associated with 28-day mortality.
Patients in critical care wards had a 111% increase
(95% CI 30 to 241%) in hazard of mortality within 28
days and patients in surgical wards a 37% decrease
(95% CI 2% increase to 61% decrease), compared to
patients in a medical ward. These values are esti-
mated at the median staffing, ward activity and risk
score values, due to interactions between ward speci-
ality and these terms.
The average staff per 10 beds was not significantly
associated with 28-day mortality, although the esti-
mated effect was greater for surgical wards (HR 0.95;
95% CI 0.63 to 1.44) compared to medicine (HR
1.00; 95% CI 0.86 to 1.16) and critical care (HR 0.99;
95% CI 0.96 to 1.02). In terms of ward activity, in a
medical ward for each increase in 1 admission or
discharge per 10 beds there was a 4% (95% CI + 1%
to + 6%) increased hazard of death within 28 days.
This increase in hazard was slightly higher in a
critical care ward (12%; 95% CI + 6% to + 19%) and
negligible in a surgical ward (3%; 95% CI − 9% to +
16%).
Patients who had moved wards within a speciality had
a 33% reduced (95% CI: − 7% to − 52%) hazard of death
within 28 days. There was also a 48% reduction (95% CI
− 76% to + 11%) for patients who had moved out of a
critical care ward. There was no evidence to suggest
movement to a critical care ward, movement from sur-
gery to medicine or from medicine to surgery impacted
on 28-day mortality.
The effect of time to receipt of appropriate antimicrobial
therapy varied depending on organism and time. There
was a highly significant effect for all organisms for each
day delay during the first week. The effect was greatest for
MSSA with a 102% increase (95% CI + 71% to + 138%) in
hazard of mortality associated with each day delay until
the receipt of first appropriate antimicrobial therapy, and
lowest for MRSA, with a corresponding 39% increase
(95% CI + 3% to + 88%) in hazard of mortality. For pa-
tients who survived to day 7, the effect of time to receipt
of first appropriate therapy on 28-day mortality was not
statistically significant after day 7. Predicted and observed
risks are given by deciles of predicted risk for 28-day mor-
tality in Supplemental Table 8, Additional file 1.
The sensitivity analyses assessing the impact of
changing the “36-h rule” in defining appropriate anti-
microbial therapy are given in Supplemental Figures 4, 5
Fig. 1 Kaplan-Meier curve for 28-day survival, by organism. Abbreviations: ESBL = Extended-spectrum beta-lactamase, MRSA- Methicillin-resistant S.
aureus, MSSA = Methicillin-susceptible S. aureus
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Table 1 Summary table of non-modifiable risk factors, by 28-day survival status
Risk factor Survived (n = 1328) Died (n = 348) Overall (n = 1676)
n % n % n %
Patient measures
Age Median (IQR) 67.0 (51.0, 79.0) 74.0 (62.0, 83.5) 68.5 (53.0, 80.0)
Male 728/1328 54.8% 191/348 54.9% 919/1676 54.8%
Body mass index a Mean (SD) 26.1 (6.7) 25.3 (5.9) 26.0 (6.6)
Patient medical history
Chemotherapy in month before date 0 201/1328 15.1% 57/348 16.4% 258/1676 15.4%
Any tumour within last 5 years 419/1328 31.6% 156/348 44.8% 575/1676 34.3%
Surgery (overnight stay) ≤7 days before date 0 118/1327 8.9% 34/348 9.8% 152/1675 9.1%
Burn requiring admission ≤7 days before date 0 3/1326 0.2% 1/347 0.3% 4/1673 0.2%
Cardiac arrest ≤7 days before date 0 5/1328 0.4% 5/348 1.4% 10/1676 0.6%
Renal support ≤7 days before date 0 81/1328 6.1% 44/348 12.6% 125/1676 7.5%
Myocardial infarction ≤7 days before date 0 128/1328 9.6% 44/348 12.6% 172/1676 10.3%
Infection severity measures
Mental Disorientation:
None 1113/1327 83.9% 257/348 73.9% 1370/1675 81.8%
Grade I 66/1327 5.0% 20/348 5.7% 86/1675 5.1%
Grade II 86/1327 6.5% 42/348 12.1% 128/1675 7.6%
Grade III 54/1327 4.1% 20/348 5.7% 74/1675 4.4%
Grade IV 8/1327 0.6% 9/348 2.6% 17/1675 1.0%
Temperature (°C) at time 0 b Mean (SD) 38.2 (1.0) 37.7 (1.2) 38.1 (1.1)
eGFR (mL/min/1.73m2) c Median (IQR) 65.0 (37.0, 90.0) 52.5 (26.5, 84.0) 62.0 (35.0, 90.0)
Serum albumin (g/L) d Mean (SD) 32.6 (7.5) 27.2 (7.9) 31.5 (7.9)
Bilirubin total (micromol /L) e Median (IQR) 12.0 (7.0, 20.5) 13.0 (8.0, 23.0) 12.0 (8.0, 21.0)
Neutrophil count at day 0 or closest (× 109/L) f Median (IQR) 9.3 (5.4, 13.8) 10.2 (4.8, 15.3) 9.5 (5.3, 14.1)
Systolic BP at day 0 or closest (mmHg) g Mean (SD) 122.9 (26.2) 117.9 (28.7) 121.9 (26.8)
On intravenous fluids at day 0 450/1324 34.0% 165/348 47.4% 615/1672 36.8%
On ventilation at day 0 90/1323 6.8% 66/348 19.0% 156/1671 9.3%
On vasopressor drugs at day 0 60/1327 4.5% 48/348 13.8% 108/1675 6.4%
Systemic corticosteroids in last 24 h 149/1324 11.3% 81/347 23.3% 230/1671 13.8%
Early warning score nearest to day 0
≤ 3 468/687 68.1% 99/173 57.2% 567/860 65.9%
> 3 219/687 31.9% 74/173 42.8% 293/860 34.1%
Patient comorbidities at date 0
Congestive heart failure 151/1328 11.4% 61/348 17.5% 212/1676 12.6%
Peripheral vascular disease 103/1328 7.8% 43/348 12.4% 146/1676 8.7%
Cerebrovascular disease 198/1328 14.9% 74/348 21.3% 272/1676 16.2%
Hemiplegia 50/1328 3.8% 18/348 5.2% 68/1676 4.1%
Dementia 99/1327 7.5% 39/348 11.2% 138/1675 8.2%
Chronic obstructive pulmonary disease 160/1327 12.1% 57/348 16.4% 217/1675 13.0%
Connective tissue disease 117/1328 8.8% 30/348 8.6% 147/1676 8.8%
Peptic ulcer disease 86/1328 6.5% 31/348 8.9% 117/1676 7.0%
Ascites 48/1328 3.6% 32/348 9.2% 80/1676 4.8%
Diabetes 276/1328 20.8% 81/348 23.3% 357/1676 21.3%
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and 6, Additional file 1. The sensitivity analyses showed
similar effects, suggesting that the chosen definition is
sensible. The complete case analysis also gave similar
results (Supplemental Figure 7, Additional file 1).
Of the 348 deaths within 28 days, just over half oc-
curred within the first 7 days (Supplemental Table 9,
Additional file 1). Across the different organisms 7-day
mortality followed a similar pattern to 28-day mortality,
patients with P. aeruginosa having the highest death rate
(20.7%) and non-ESBL-producing E. coli the lowest
(5.2%). The analyses indicated that ward speciality, ward
activity, movements within ward specialities, and time to
receipt of appropriate antimicrobial therapy in the first 5
days were all risk factors associated with mortality
within 7 days, after adjustment for other factors (Fig. 3
and Supplemental Table 10, Additional file 1).
Table 1 Summary table of non-modifiable risk factors, by 28-day survival status (Continued)
Risk factor Survived (n = 1328) Died (n = 348) Overall (n = 1676)
n % n % n %
Modified Child-Pugh score h Median (IQR) 6.0 (6.0, 7.0) 7.0 (6.0, 8.0) 7.0 (6.0, 8.0)
Modified Charlson score i Median (IQR) 3.0 (2.0, 4.0) 4.0 (2.0, 5.0) 3.0 (2.0, 4.0)
Infected foreign body at time 0 16/1327 1.2% 3/347 0.9% 19/1674 1.1%
Source of infection (CDC criteria)
Bone and joint 59/1327 4.4% 6/348 1.7% 65/1675 3.9%
Cardiovascular system 25/1327 1.9% 5/348 1.4% 30/1675 1.8%
Central nervous system 9/1327 0.7% 0/348 0.0% 9/1675 0.5%
Eye, ear, nose, throat or mouth 3/1327 0.2% 1/348 0.3% 4/1675 0.2%
Gastrointestinal system 134/1327 10.1% 16/348 4.6% 150/1675 9.0%
Line infection – central venous line 123/1327 9.3% 15/348 4.3% 138/1675 8.2%
Line infection – peripheral venous line 20/1327 1.5% 7/348 2.0% 27/1675 1.6%
Lower respiratory tract 61/1327 4.6% 57/348 16.4% 118/1675 7.0%
Reproductive tract 9/1327 0.7% 2/348 0.6% 11/1675 0.7%
Skin and soft tissue 98/1327 7.4% 20/348 5.7% 118/1675 7.0%
Surgical site infection 37/1327 2.8% 4/348 1.1% 41/1675 2.4%
Urinary tract infection 386/1327 29.1% 61/348 17.5% 447/1675 26.7%
Site uncertain 363/1327 27.4% 15,446/348 44.3% 517/1675 30.0%
Organisational factors
Admission from nursing home 97/1327 7.3% 40/348 11.5% 137/1675 8.2%
Length of prior hospital stay (days) Median (IQR) 1.0 (0.0, 10.0) 5.0 (0.0, 14.0) 1.0 (0.0, 11.0)
Hospital or community acquired infection
Hospital 548/1328 41.3% 201/348 57.8% 749/1676 44.7%
Community 780/1328 58.7% 147/348 42.2% 927/1676 55.3%
Speciality of consultant on day 0:
Medicine 559/1217 45.9% 171/333 51.4% 730/1550 47.1%
High dependency medicine 202/1217 16.6% 80/333 24.0% 282/1550 18.2%
Major surgery 355/1217 29.2% 60/333 18.0% 415/1550 26.8%
Minor surgery 9/1217 0.7% 3/333 0.9% 12/1550 0.8%
Other 92/1217 7.6% 19/333 5.7% 111/1550 7.2%
Abbreviations: SD Standard deviation, IQR Interquartile range, eGFR Estimated glomerular filtration rate, BP Blood pressure, CDC Centres for Disease Control
and Prevention
a Data missing for 799 patients (604 survived, 195 died)
b Data missing for 30 patients (20 survived, 10 died)
c Data missing for 118 patients (98 survived, 20 died)
d Data missing for 200 patients (161 survived, 39 died)
e Data missing for 267 patients (216 survived, 51 died)
f Data missing for 139 patients (110 survived, 29 died)
g Data missing for 246 patients (196 survived, 50 died)
h Data missing for 1075 patients (867 survived, 208 died)
i Data missing for 377 patients (299 survived, 78 died)
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Discussion
This report describes modifiable risk factors for 28-
day mortality in patients with bloodstream infection
due to one of six key pathogens. Our main findings
were that:
 For all the pathogen groups studied timely
appropriate antimicrobial therapy was associated
with improved mortality over 28 days, and the effect
of each day delay was most marked in the first 7
days.
 Increased ward activity (admissions and discharges)
was associated with increased hazard of death within
medical wards and especially in critical care wards.
The analysis of risk factors for mortality was split into
those classified as non-modifiable factors and those that
could be modified by changes in organisation or patient
management. For the pathogen groups studied, ward
speciality, ward activity, ward movement within special-
ity, movement from critical care and time to receipt of
appropriate antibiotics were all independently associated
with mortality.
The reduced hazard of death within 28 days for
patients who moved wards within ward specialty or had
moved out of a critical care ward could be a result of
healthier patients being more likely to be moved or a
result of improving condition. Similarly, the association
between ward specialty and mortality is likely to be
related to the severity and complexity of patients admit-
ted to the ward.
There are a large number of publications relating
organisational and management factors to infection
control performance in acute hospitals including work-
force and workload [18]. However, there are no previous
studies relating ward staffing and activity to infection
outcomes. In our descriptive analysis of modifiable
factors, patients who died were on wards where the aver-
age number of nurses per 10 beds on day 0 was slightly
higher than for those who survived, but this may reflect
the higher mortality in intensive care units where nurs-
ing staffing was much higher. After adjustment for other
factors there was no evidence of a statistically significant
effect of staffing levels on 28-day mortality. Interestingly,
the number of NHS-employed nurses, healthcare assis-
tants or agency staff working did not vary greatly by day
Table 2 Ward speciality, ward movements, staffing and ward activity, by 28-day survival status
Ward variable Survived (n = 1328) Died (n = 348) Overall (n = 1676)
n % n % n %
Ward speciality on day 0
Medicine 738/1316 56.1% 186/345 53.9% 924/1661 55.6%
Critical care 138/1316 10.5% 96/345 27.8% 234/1661 14.1%
Major surgery 355/1316 27.0% 50/345 14.5% 405/1661 24.4%
Minor surgery 22/1316 1.7% 3/345 0.9% 25/1661 1.5%
Other 63/1316 4.8% 10/345 2.9% 73/1661 4.4%
Type of ward movements between day 0 and 7
Movement to critical care 87/1301 6.7% 30/337 8.9% 117/1638 7.1%
Movement from critical care 98/1301 7.5% 8/337 2.4% 106/1638 6.5%
Movement within a ward speciality 347/1301 26.7% 48/337 14.2% 395/1638 24.1%
Movement from medicine to surgery 82/1301 6.3% 7/337 2.1% 89/1638 5.4%
Movement from surgery to medicine 30/1301 2.3% 5/337 1.5% 35/1638 2.1%
Staffing and ward activity on day 0
Average number of nurses per 10 beds a Median (IQR) 1.4 (1.1, 2.1) 1.7 (1.2, 7.0) 1.4 (1.1, 2.4)
Average number of HCA per 10 beds b Median (IQR) 0.6 (0.4, 0.8) 0.7 (0.4, 0.9) 0.6 (0.4, 0.8)
Average number of agency staff per 10 beds c Median (IQR) 0.0 (0.0, 0.3) 0.1 (0.0, 0.3) 0.0 (0.0, 0.3)
Average number of total staff per 10 beds d Median (IQR) 2.3 (1.9, 2.8) 2.6 (2.0, 7.4) 2.3 (1.9, 3.1)
Ward activity per 10 beds e f Median (IQR) 3.7 (1.9, 7.3) 3.5 (1.8, 5.5) 3.7 (1.9, 6.9)
Abbreviations: HCA Healthcare assistant
a Data missing for 276 patients (234 survived, 42 died)
b Data missing for 277 patients (235 survived, 42 died)
c Data missing for 288 patients (245 survived, 43 died)
d Data missing for 300 patients (255 survived, 45 died)
e Data missing for 153 patients (133 survived, 20 died)
f Ward activity is defined as the number of patients admitted + number of patients discharged
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of week, although nurse numbers were slightly lower at
the weekend. However, ward activity was markedly lower
at weekends – which is perhaps not surprising despite
the current drive in the NHS towards a 7 day working
week [19]. Ward activity was highest on the day blood
samples were taken and diminished over the following
week, possibly as patients are moved from high activity
settings such as emergency departments or admissions
units to wards having more stable populations of pa-
tients undergoing recovery. It has been shown that in-
creasing exposure to shifts with high turnover of
patients is associated with an increase in the risk of
death, however there is less information on the impact
of workload on infection outcomes in particular [20]. In
an adjusted model where ward activity was updated daily
to reflect the ward activity where the patient spent most
of the day, increased ward activity was associated with
an increased hazard of death within 28 days.
Appropriate antimicrobial therapy has been shown to
reduce mortality based on a large number of publica-
tions over the last 20 years [21]. There are several more
recent systematic reviews and meta-analyses indicating
that appropriate antimicrobial therapy has survival bene-
fit in both BSI [22] and severe sepsis [23, 24]. Our data
shows that delays in administration of appropriate anti-
microbials impact on outcome in BSI over days 0–6.
Strengths and limitations
This is one of the largest observational cohort studies of
patients with BSI in the NHS. A key strength of the
study is that it did not require individual patient consent
therefore reducing the risk of selection bias. For ex-
ample, less acutely ill patients may be more likely to be
approached and consent which could undermine the sci-
entific integrity and public value of the research. The
National Information Governance Board approved the
Fig. 2 Adjusted Cox model of modifiable risk factors on 28-day mortality. a Effect of organism is given for the time period 0 to 6 days, when time
to appropriate therapy is 1 day. b Effect of ward speciality is given for the median number of staff per 10 beds, median ward activity and median
risk score. Abbreviations: ESBL = Extended-spectrum beta-lactamase, MRSA- Methicillin-resistant S. aureus, MSSA = Methicillin-susceptible S. aureus,
CI=Confidence interval
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use of such routinely collected data without individual
patient consent under section 251 of the NHS Act 2006.
A large number of data items were collected which en-
abled us adequality control for potential confounding
in the analysis and also allowed us to include variables
that are predictive of missing data in a covariate of
interest in the multiple imputation procedure making
the missing at random assumption plausible. There are
some limitations of the study. Firstly, focussing on six
key pathogens may limit the generalisability of the re-
sults. This study focused on patients with clinically sig-
nificant pathogens that produce large numbers of
infections and may have multidrug resistance. We spe-
cifically focused on pathogens that were highly unlikely
to be contaminants but were also common cases of BSI,
linked with significant mortality and remain a signifi-
cant problem across the NHS. Results may not be
generalisable to other bloodstream infections and there-
fore conclusions drawn should be limited to the six key
pathogens studied. Finally, this study focussed on NHS-
employed nurses, health- care assistants and agency
nurses, but did not explore the impact of other medical
staffing levels such as consultants which may merit ana-
lysis in future research.
Conclusions
Our overall conclusion is that for all the pathogen groups
studied timely appropriate antimicrobial therapy was asso-
ciated with improved clinical outcome as measured by
mortality over 28 days, and the effect of each day delay
was most marked in the first 7 days. In addition, increased
ward activity (admissions and discharges) was associated
with increased hazard of death within medical wards and
especially in critical care wards.
Fig. 3 Adjusted Cox model of modifiable risk factors on 7-day mortality. a Effect of organism is given for the time period 0 to 5 days and when
time to appropriate therapy is 1 day. b Effect of ward speciality is given for the median number of staff per 10 beds, median ward activity and
median risk score. Abbreviations: ESBL = Extended-spectrum beta-lactamase, MRSA- Methicillin-resistant S. aureus, MSSA =Methicillin-susceptible S.
aureus, CI=Confidence interval
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